CCR1 and rheumatoid arthritis: Anti-CCR1 antibody treatment blocked CCL5/RANTES-induced migration of RA monocytes (1 μg/ml, P = 0.0011; 5 μg/ml, P = 0.0280 compared to isotype control) (Fig. 4A).